Right to Try Legislation: Worthwhile or Window Dressing?

Published date13 April 2018
Law FirmTroutman Pepper
AuthorMelissa Hatch O’Donnell,Donna Fisher,Samuel Abate Jr.
Subject MatterFDA,Life Sciences,Proposed Legislation,Preemption,FDCA,Clinical Trials,Prescription Drugs,Legislative Agendas,Biopharmaceutical,Right to Try,Regulatory Oversight,Pharmaceutical Industry,Expanded Access Programs (EAPs),Terminal Illness Treatments,Patient Access

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT